MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

Catalent Signs Agreement to Take Over Juniper Pharmaceuticals, Inc

    Catalent Signs Agreement to Take Over Juniper Pharmaceuticals, Inc

Catalent, Inc, on Monday, signs an agreement to acquire Juniper Pharmaceuticals, Inc. along with its UK-based center in Nottingham. Catalent wrapped up the deal for $ 11.50 per share in cash.

“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” said Jonathan Arnold, President of Catalent Oral Drug Delivery.

With the acquisition, Catalent will boost its offerings in the field of formulation development, bioavailability, and robot manufacturing and will balance its amalgamated global clinical and business supply units.

In its Nottingham centre, Juniper accommodates around 150 workers which are specialized in the field of formulation development. Hence, it’s an added advantage to the company for having a team of skilled workers, as they are responsible for redefining the old profile.

The old profile includes sophisticated transmission, articulation, formulation, critical, and pharmacology improvement solutions, including augmentation of integrated development, reasonable, and technical manufacturing.

Catalent deals with technology and development solutions for medicines and consumer health goods across the world. It has branches over several countries which include the UK, the USA and several parts of Asia and Europe.

“Juniper’s scientific expertise in early-phase product development and supply will help our customers to unlock the full potential of their molecules and provide better and faster treatments to patients,” said Mr. Arnold.

 

 

 

 

 

 

 

 

 

 

YOU MAY ALSO LIKE

Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...

Business Travelers to Stay at Singapore’s Changi Airport Bubble

Singapore’s open economy depends heavily on tourism and business. But its vibrant but small economy has been hurting as the circumstances due to...

Countries in Asia-Pacific are marching towards ‘green recovery’ amidst Covid-19 crisis

2020 has been an unforgettable year for many of us. The ongoing Covid crisis has reminded people that it is very important to have an uninterrupted an...

Department of Telecommunication to announce the new schedule for 5G trials

Department of Telecommunications (DoT) is all set to announce the new schedule for 5G trials. The Dot made this decision after being pulled by the par...

RECOMMENDED